featured
Circulating ESR1 Mutations at the End of Aromatase Inhibitor Adjuvant Treatment and After Relapse in Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Breast Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Circulating ESR1 Mutations at the End of Aromatase Inhibitor Adjuvant Treatment and After Relapse in Breast Cancer Patients
Breast Cancer Res 2018 May 16;20(1)40, V Allouchery, L Beaussire, A Perdrix, D Sefrioui, L Augusto, C Guillemet, N Sarafan-Vasseur, F Di Fiore, F ClatotFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.